Live Breaking News & Updates on Papyrus Therapeutics Inc

Stay updated with breaking news from Papyrus therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Oxford Biomedica PLC Announcements | Oxford Biomedica PLC: Full year results


 

I am truly proud of the Group s achievements over the period. We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for COVID-19. This is a true testament to the world-class calibre and dedication of our staff in the year that the Group also gained entry to the FTSE250. Looking to the future, with the continued tide of growth in cell and gene therapy, coupled with the Group s leadership position in the lentiviral vector field, we are well positioned to advance both our own proprietary pipeline and that of our current and future partners programmes. ....

United Kingdom , Sam Rasty , Pierre Fabre , Mary Jane Elliott Matthew Neal , Stuart Paynter , Andrew Heath , Roch Doliveux , Oxford Astrazeneca , Oxford Biomedica Lentivector , John Dawson , Martin Diggle , Oxford Biomedica , Bristol Myers Squibb , Lorenzo Tallarigo , Juno Bristol Myers Squibb , Dame Kay Davies , Manufacturing Organisation , Contract Development , Oxford University Jenner Institute , Research Collaborations , Senior Executive Team , Boehringer Ingelheim , Stryker Corporation , Product Development , Juno Therapeutics Bristol Myers Squibb Partnership , Innovation Centre ,

Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality


Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
- The parties will explore the feasibility and effect of combining their respective oncolytic virus and receptor tyrosine kinase (RTK) inhibitor technologies
- Targovax retains the right to develop and commercialize novel drug candidates emerging from the pre-clinical collaboration
News provided by
Share this article
OSLO, Norway, Feb. 10, 2021 /PRNewswire/
Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into a research collaboration agreement with Papyrus Therapeutics to assess the potential of combining their respective proprietary technology platforms to develop a first-in-class oncolytic virus concept with RTK inhibitor functionality.   ....

United States , Prnewswire Targovax , Victor Levitsky , Andreas Tinglum , Renate Birkeli , Paul Blake , Kim Sutton Golodetz , Corporate Communications Norway , Papyrus Therapeutics Inc , Papyrus Therapeutics , Opioid Binding , Cell Adhesion Molecule Like , Chief Executive Officer , Chief Scientific Officer , Sutton Golodetz , ஒன்றுபட்டது மாநிலங்களில் , வெற்றியாளர் லெவிட்ஸ்கி , பால் பிளேக் , பெருநிறுவன தகவல்தொடர்புகள் நோர்வே , பாப்பிரஸ் சிகிச்சை இன்க் , பாப்பிரஸ் சிகிச்சை , ஓபியாய்டு பிணைப்பு , தலைமை நிர்வாகி அதிகாரி , தலைமை அறிவியல் அதிகாரி ,